Neutral impactCompany
Explained: Why Morgan Stanley has the second-lowest price target on the Street for this drugmaker
CNBC-TV18 56 min ago·4 Sept 2026, 7:58 am
Morgan Stanley has set the second-lowest price target on the Street for Cipla, a major Indian drugmaker. This cautious stance comes despite the firm viewing the company's recent exclusive US licensing deal with Qilu Pharmaceutical for the Keytruda biosimilar QL2107 as a positive development for its oncology portfolio.
For investors, this divergence highlights a difference in how analysts view Cipla's growth potential. While the deal is seen as a strategic win for expanding into the high-value US market, the lower target suggests Morgan Stanley is prioritizing other factors, such as pricing pressures or competition, that could limit the stock's upside in the near term.
Investors should watch for upcoming earnings reports and any updates on the commercial launch of QL2107. The stock's performance will likely depend on whether Cipla can successfully navigate the competitive US biosimilar market and justify a higher valuation compared to its peers.
Key takeaways
- Category: Company.
Why it matters
A routine update. Use the price and stock snapshot to gauge how the market is responding.
